Ginkgo Bioworks Holdings, Inc. reported $112M of revenue over the trailing twelve months, −47% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $112M (to Q2 2026). Net income: −$291M, trailing twelve months to Q2 2026. Free cash flow: −$175M, trailing twelve months to Q2 2026. Operating margin: −275%, trailing twelve months to Q2 2026.

DNAGinkgo Bioworks Holdings, Inc.

Healthcare

$11.34-23% 1Y

$11.34

$5.4852 weeks$16.09

DNA as reported

Ginkgo Bioworks Holdings, Inc. reported $112M of revenue over the trailing twelve months, −47% on the year before. 8 reported series are charted on this page, each one as filed.

$112M

Revenue, trailing twelve months · to Q2 2026 · −47% against the twelve months before

Net income: −$291M
Net income · −7.7% year on year · trailing twelve months to Q2 2026
Free cash flow: −$175M
Free cash flow · −36% year on year · trailing twelve months to Q2 2026
Operating margin: −275%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for DNA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$112M	−47%	Q2 2026
Net income	−$291M	−7.7%	Q2 2026
EPS	−$5.65	n/a	Q4 2025
Operating margin	−275%	n/a	Q2 2026
Net margin	−276%	n/a	Q2 2026
ROE	−65%	n/a	Q2 2026
ROA	−29%	n/a	Q2 2026
Free cash flow	−$175M	−36%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.